GHRH analog combined with selective GH secretagogue. Pulsatile growth hormone release without prolactin spike.
CJC-1295 is a long-acting GHRH analog (DAC variant has ~8 day half-life; non-DAC ~30 min). Ipamorelin is a selective ghrelin receptor agonist that triggers GH release without elevating ACTH/cortisol/prolactin. Stacked use yields amplified pulsatile GH at lower side-effect cost than synthetic HGH.
Confusion between CJC-1295 with-DAC and without-DAC is common; profiles differ substantially. Long-term safety of sustained GH elevation is undefined.
CJC-1295 chain shown; Ipamorelin is a 5-residue cyclic structure with two unnatural amino acids (Aib, D-2-Nal, D-Phe).
Same mechanism class — adds cost without adding signal.
Stack doesn't rank peptides — we surface the diversity of opinion. Each card paraphrases a public-record stance from a named source. Where they conflict is where you should slow down and read both.
CJC-1295 (no-DAC) + Ipamorelin nightly was the canonical 503A compounding-pharmacy GH-pulse stack pre-Cat-2 ban. Most peptide-friendly clinics in the US prescribed this combo for body-recomposition + sleep architecture. Post-2023 the legal access path tightened; many users moved to grey-market.
C-tier — "really a mild effect compared to the real deal growth hormone. You can get underground GH for less than what a clinic would charge for these. I'm just like — what are we doing here?"
Multiple small trials confirm CJC-1295 + Ipamorelin produces measurable IGF-1 elevation and slow-wave sleep improvement vs placebo over 4-12 weeks. Effect size is real but modest. Long-term cancer-promotion concerns from sustained IGF-1 elevation are unresolved.
Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Pre-filled with this compound's published dose range: 100-300 µg · nightly, subcutaneous
Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.
How much a first cycle actually costs across the channels people use. Pick the protocol length you're considering — Stack multiplies the monthly band by cycle weeks. Same caveats apply: ranges are facts, quality varies, this is not legal advice.
Numbers reflect publicly-advertised price ranges, not vendor quotes. Insurance, prescription costs, and shipping aren't included. Channels marked unavailable are filtered out.
See pharmacies for this compound →Approximate monthly cost across the channels users actually consider — brand FDA-approved retail, US 503A compounding, Mexican pharmacies, MX farmacias magistrales, and the research-grey market. Stack lists ranges, not vendor names. Quality varies wildly across channels — see each band's note.
Dosing assumption: 100-200 mcg Ipamorelin + ~100 mcg CJC-1295 nightly (no-DAC formulation)
503A pharmacies with prescription. Currently FDA Cat-1 (compoundable). Pricing has been stable through the broader peptide regulatory shifts.
As of 2026-04MX farmacias magistrales — comparable quality, lower price point.
As of 2026-04Research-grey range. Identity and concentration verification poor without third-party testing.
As of 2026-04Public-source attribution across the production + distribution chain. Stack does not endorse vendors — this is who is in the chain, not which one is best.
Swiss-headquartered global peptide API manufacturer with FDA-registered facilities. Supplies APIs to multiple FDA-approved drug brands.
US-based peptide CRDMO with metric-ton scale GMP API capacity.
BPC-157 · TB-500 · Sermorelin · CJC-1295/Ipamorelin · Semaglutide · Tirzepatide
Houston-based 503A compounding pharmacy, one of the largest in the US peptide compounding market.
BPC-157 · TB-500 · Sermorelin · CJC-1295/Ipamorelin
BPC-157 · Sermorelin · CJC-1295/Ipamorelin
Sermorelin · Ipamorelin · BPC-157
One of the most consistently recommended vendors on r/Peptides since the Peptide Sciences shutdown (March 2026). Third-party COA published per batch. HPLC purity ≥99%.
For laboratory use only / not for human consumption. Stack may earn affiliate commissions.
Long-established US vendor (7+ years). Broad catalog including GHRPs, GHRHs, and cognitive peptides. Third-party HPLC and mass-spec COA per batch. Active Finnrick Analytics coverage.
For laboratory use only / not for human consumption. Stack may earn affiliate commissions.
Newer vendor with fast turnaround and competitive pricing. Third-party COA on all products. Building Finnrick coverage. Frequently recommended post-Peptide Sciences shutdown.
For laboratory use only / not for human consumption. Stack may earn affiliate commissions.
Established vendor with multi-year community track record. Offers peptide blends (Wolverine Stack, etc.) alongside singles. Third-party COA available on request.
For laboratory use only / not for human consumption. Stack may earn affiliate commissions.
Known for above-average catalog depth, including harder-to-find compounds (SS-31, humanin, Foxo4-DRI). Third-party HPLC published. Active Finnrick coverage.
For laboratory use only / not for human consumption. Stack may earn affiliate commissions.
Clean storefront, competitive pricing, strong community mentions. Third-party COA on most products. Ships to US with fast turnaround.
For laboratory use only / not for human consumption. Stack may earn affiliate commissions.
Tampa-based telehealth clinic specializing in hormone and peptide therapy. Prescribing provider + compounding pharmacy fulfillment. BPC-157, CJC/Ipa, Ipamorelin, PT-141, Sermorelin. Prescription required.
For laboratory use only / not for human consumption. Stack may earn affiliate commissions.
FDA Cat. 1 — compounding pharmacies
COFEPRIS regulates Mexican farmacias magistrales (compounding pharmacies) under different rules than the US 503A bulks-list framework. Several Mexican compounding pharmacies prepare BPC-157, TB-500, CJC-1295/Ipamorelin, Tesamorelin, and GHK-Cu without the FDA Category 2 ban that has constrained US compounding since 2023.